Standout Papers
Citation Impact
Citing Papers
Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism
2004
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
The management of heparin‐induced thrombocytopenia
2006
Heparin-induced thrombocytopenia (HIT)
2006
Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms.
2017 Standout
Parenteral Anticoagulants
2008
Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia
2013
Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis
2001
Parenteral Anticoagulants
2012 Standout
Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia
2001
Danaparoid for heparin‐induced thrombocytopenia: an analysis of treatment failures
2003
Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia
2002
Affinity purification of heparin‐dependent antibodies to platelet factor 4 developed in heparin‐induced thrombocytopenia: biological characteristics and effects on platelet activation
2000
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?
2005
Cerebral venous and sinus thrombosis
2004
Mechanisms of Thrombus Formation
2008 Standout
Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia in Elderly Patients
2007
Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy
2004
Heparin-Induced Thrombocytopenia
2000
Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‐dependent antibodies
2005
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin-Induced Thrombocytopenia: A Serious Complication of Heparin Therapy for Acute Stroke
2008
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Effects of Argatroban Therapy, Demographic Variables, and Platelet Count on Thrombotic Risks in Heparin-Induced Thrombocytopenia
2006
Inflammation in autoimmunity: receptors for IgG revisited
2001
Heparin-induced thrombocytopenia in the emergency department
2004
Argatroban for anticoagulation during cardiac surgery
2006
Heparin‐induced thrombocytopenia: pathogenesis and management
2003
Laboratory Testing for Heparin-Induced Thrombocytopenia
2000
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
2004
Bivalirudin: a review
2005
Incidence and Economic Implications of Heparin‐Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism
2006
Fc receptors and their interaction with complement in autoimmunity
2005
Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban
2003
Heparin-Induced Thrombocytopenia Following Cardiac Surgery is Associated With Poor Outcome
2006
Drug-Induced Thrombocytopenia
2007
Transition to an Oral Anticoagulant in Patients With Heparin-Induced Thrombocytopenia
2005
Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia
2004
Venous Thromboembolism Is Rare with a Multimodal Prophylaxis Protocol after Total Hip Arthroplasty
2006
Integrins Form an Expanding Diffusional Barrier that Coordinates Phagocytosis
2016 StandoutNobel
Risk of Anaphylaxis After Reexposure to Intravenous Lepirudin in Patients With Current or Past Heparin-Induced Thrombocytopenia
2005
A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
2008
Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
2003
Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin‐induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports
2001
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes
2007
The Incidence of Recognized Heparin-Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital
2007
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
HEPARIN‐INDUCED THROMBOCYTOPENIA IN DIALYSIS: Alternative Methods of Anticoagulation for Dialysis‐dependent Patients with Heparin‐induced Thrombocytopenia
2003
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Severe Sepsis and Septic Shock
2013 Standout
Heparin‐induced thrombocytopenia from venous thromboembolism treatment
2005
Transitioning from Argatroban to Warfarin in Heparin-Induced Thrombocytopenia: An Analysis of Outcomes in Patients with Elevated International Normalized Ratio (INR)
2005
Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
1999
Fcγ receptors as regulators of immune responses
2007 Standout
Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease
2004
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Bivalent direct thrombin inhibitors: hirudin and bivalirudin
2004
Risk factors for thrombosis in patients with immune mediated heparin‐induced thrombocytopenia
2002
Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia
2004
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
High‐dose intravenous immunoglobulin to treat spontaneous heparin‐induced thrombocytopenia syndrome
2019
Is cognitive impairment associated with suicidality? A population-based study
2014
Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study
2014
Thrombocytopenia in Patients With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE])
2008
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005
Diagnostic score for heparin‐induced thrombocytopenia after cardiopulmonary bypass
2004
Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparin
2002
Twice vs Three Times Daily Heparin Dosing for Thromboembolism Prophylaxis in the General Medical Population
2007
What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?
2007
Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin‐Induced Thrombocytopenia
2005
The Relationship Between Hirudin and Activated Clotting Time: Implications for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiac Surgery
2001
Heparin-Induced Thrombocytopenia
2006 Standout
Quantitative interpretation of optical density measurements using PF4‐dependent enzyme‐immunoassays
2008
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation
2005
Autoimmune heparin‐induced thrombocytopenia
2017
Argatroban therapy in heparin-induced thrombocytopenia
2008
Excessive Anticoagulation and Anaphylactic Reaction After Rechallenge with Lepirudin in a Patient with Heparin‐Induced Thrombocytopenia
2004
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-induced thrombocytopenia and cardiac surgery
2003 Standout
Testing for Heparin-Induced Thrombocytopenia Antibodies
2006
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2012
A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II
2000
The Cost-Effectiveness of Argatroban Treatment in Heparin-Induced Thrombocytopenia
2005
Heparin-induced thrombocytopenia and cardiac surgery
2003
Safety of Warfarin Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
1999
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Evaluation of Bivalirudin Treatment for Heparin‐Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal Dysfunction
2006
Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo
2008
Think of HIT
2006
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia
2002
Antithrombotic Therapy in Neonates and Children
2008
The creation of an antithrombotic surface by apyrase immobilization
2010 StandoutNobel
The Pathophysiology of Heparin-Induced Thrombocytopenia
2005
Heparin‐induced multi‐electrode aggregometry method for heparin‐induced thrombocytopenia testing: communication from the SSC of the ISTH
2016
Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin‐induced thrombocytopenia
2004
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
A Case Review: Anticoagulation in Hemodialysis Patients with Heparin-Induced Thrombocytopenia
2001
Argatroban
2009
Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s
2005
Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery
2004
Vascular bed-specific thrombosis
2007
Heparin-Induced Thrombocytopenia in Patients Administered Heparin Solely for Hemodialysis
2006
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Thrombocytopenia Associated with Antithrombotic Therapy in Patients with Cardiovascular Diseases
2008
Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
2008
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Identification of the platelet ADP receptor targeted by antithrombotic drugs
2001 StandoutNatureNobel
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia
2016
Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines
2012
Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)
2008
Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant
2000
Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study
2012
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis
2001
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies
2000
On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran®) in Patients With Heparin-Induced Thrombocytopenia
2003
Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report.
2006
Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis
2001
A Comparison of Lepirudin and Argatroban Outcomes
2005
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study
2005
Fondaparinux: A potential new therapy for HIT
2005
High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin‐induced thrombocytopenia antibodies
2013
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
2005
Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels
2017 StandoutNobel
Platelet Factor 4/Heparin Antibodies in Blood Bank Donors
2010
Delayed-Onset Heparin-Induced Thrombocytopenia
2002
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Thrombocytopenia in the Intensive Care Unit Patient
2010
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin
2005
Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease
2013
B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia
2013
CalDAG-GEFI deficiency protects mice in a novel model of FcγRIIA-mediated thrombosis and thrombocytopenia
2011
Anticoagulation during Cardiopulmonary Bypass in Patients with Heparin-induced Thrombocytopenia Type II and Renal Impairment Using Heparin and the Platelet Glycoprotein IIb–IIIa Antagonist Tirofiban
2001
Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia
2005
Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: Use of heparin and epoprostenol combined with on-line monitoring of platelet function
2000
Contribution of Bleeding and Thromboembolic Events to In-Hospital Mortality Among Patients With Thrombocytopenia Treated With Heparin
2009
Interpreting the International Normalized Ratio (INR) in Individuals Receiving Argatroban and Warfarin
2001
Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia
2006
Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated With R-Hirudin
1999
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients
2007
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody
2002
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Is cognitive impairment associated with suicidality? A population-based study
2014
Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia
2003
Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface
2002 StandoutNobel
Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues
2009
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism
2013 Standout
Randomized Trial of Prevention of Catheter-Related Bloodstream Infection by Continuous Infusion of Low-Dose Unfractionated Heparin in Patients With Hematologic and Oncologic Disease
2005
ADP Receptors and Clinical Bleeding Disorders
1999
Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital
2006
Unfractionated LMWH and the risk of HIT: are medical patients different?
2005
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
2005
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients
2000
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
2005 Standout
ESPGHAN and ESPEN Guidelines Paediatric Parenteral Nutrition ‐ Annex: List of Products
2005 Standout
Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Requiring Renal Replacement Therapy
2005
Effects of Disturbed Flow on Vascular Endothelium: Pathophysiological Basis and Clinical Perspectives
2011 Standout
Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation
2001
Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients
2007
Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin
1999
Physiology of Microglia
2011 Standout
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Works of Petra Eichler being referenced
Executive performance of depressed suicide attempters: the role of suicidal ideation
2008
Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia
2006
Heparin-Induced Thrombocytopenia
2002
Thromboembolieprophylaxe als Auslöser thrombembolischer Komplikationen
2008
Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use
2003
Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes
2007
Very Low Platelet Counts in Post-transfusion Purpura Falsely Diagnosed as Heparin-induced Thrombocytopenia
2000
Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced thrombocytopenia
2001
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis
2005
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings
2006 Standout
The new ID‐heparin/PF4 antibody test for rapid detection of heparin‐induced antibodies in comparison with functional and antigenic assays
2002
A Prospective Study on the Incidence and Clinical Relevance of Heparin-Induced Antibodies in Patients after Vascular Surgery
2000
Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support
2006
Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial
2003
Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin)
1998
Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3
2005
DRUG ‐INDUCED AND DRUG ‐DEPENDENT IMMUNE THROMBOCYTOPENIAS
2001
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
2006
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
2000
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
2004
Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies
2004
Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
1999
Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin
2003
A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia
2001
Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the FcγRIIa-R-H131 Polymorphism
1998
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance
2000
Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia
2003
Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients
1998
Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance
2003
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance
2000
First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA
1999
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
2000
Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia
2005
Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
1999
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study
2003